Apolipoprotein E gene therapy
Latest Information Update: 08 Jul 2002
Price :
$50 *
At a glance
- Originator Aventis; Nonindustrial source
- Class Antihyperlipidaemics; Gene therapies
- Mechanism of Action Apolipoprotein E agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hypercholesterolaemia
Most Recent Events
- 14 Feb 2000 New profile
- 14 Feb 2000 Preclinical development for Hypercholesterolaemia in France (Parenteral)